Marcello Rattazzi

Prof. Marcello Rattazzi

Università degli Studi di Padova, Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2006 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
BBBrian J. Bennett
Brian J. Bennett
MSMarta Scatena
Marta Scatena
EKElizabeth A. Kirk
Elizabeth A. Kirk
MRMarcello Rattazzi
Marcello Rattazzi
RVRebecca M. Varon
Rebecca M. Varon
MRMichael E. Rosenfeld
Michael E. Rosenfeld
Objective— Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) superfamily of proteins, plays an important role in bone remodeling and is expressed in both mouse and human atherosclerotic lesions. The current study was designed to assess whether OPG plays a role in the progression and calcification of advanced atherosclerotic lesions in apoE −/− mice. Methods and Results— Atherosclerotic lesion area and composition and aortic calcium content were examined in mice deficient in both OPG and apolipoprotein E ( OPG −/− .apoE −/− mice) at 20, 40, and 60 weeks of age. Littermate OPG +/+ .apoE −/− mice were used as controls. The average cross-sectional area of lesions in the innominate arteries was increased in OPG −/− .apoE −/− mice at 40 and 60 weeks of age. The increase in lesion area was coupled with a reduced cellularity and an increase in connective tissue including laminated layers of elastin. Sixty-week-old OPG −/− .apoE −/− mice also had an increase in the area of calcification of the lesions. There were no differences in markers of plaque stability. In vitro, OPG induced matrix metalloproteinase-9 (MMP-9) activity in macrophages and smooth muscle cells and acted as a survival factor for serum-deprived smooth muscle cells. Conclusion— OPG inhibits advanced plaque progression by preventing an increase in lesion size and lesion calcification. OPG may act as a survival factor and may modulate MMP9 production in vascular cells.

1 July 2005 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
MRMarcello Rattazzi
Marcello Rattazzi
BBBrian J. Bennett
Brian J. Bennett
FBFlorian Bea
Florian Bea
EKElizabeth A. Kirk
Elizabeth A. Kirk
JRJerry L. Ricks
Jerry L. Ricks
MRMichael E. Rosenfeld
Michael E. Rosenfeld
Objective— Advanced atherosclerotic lesions in the innominate arteries of chow-fed apolipoprotein E–deficient mice become highly calcified with 100% frequency by 75 weeks of age. The time course, cell types, and mechanism(s) associated with calcification were investigated. Methods and Results— The deposition of hydroxyapatite is preceded by the formation of fibro-fatty nodules that are populated by cells that morphologically resemble chondrocytes. These cells are spatially associated with small deposits of hydroxyapatite in animals between 45 and 60 weeks of age. Immunocytochemical analyses with antibodies recognizing known chondrocyte proteins show that these cells express the same proteins as chondrocytes within developing bone. Histological and electron microscopic analyses of lesions from animals between 45 and 60 weeks of age show that the chondrocyte-like cells are surrounded by dense connective tissue that stains positive for type II collagen. Nanocrystals of hydroxyapatite can be seen within matrix vesicles derived from the chondrocyte-like cells. In mice between 75 and 104 weeks of age, the lesions have significantly reduced cellularity and contain large calcium deposits. The few remaining chondrocyte-like cells are located adjacent to or within the large areas of calcification. Conclusions— Calcification of advanced lesions in chow-fed apolipoprotein E–deficient mice occurs reproducibly in mice between 45 and 75 weeks of age. The deposition of hydroxyapatite is mediated by chondrocytes, which suggests that the mechanism of calcification may in part recapitulate the process of endochondral bone formation.

6 February 2006 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
PPPaolo Pauletto
Paolo Pauletto
MRMarcello Rattazzi
Marcello Rattazzi
The last decade has shown an increase in the relevance of inflammation and its mediators in vascular biology; thus, the role of inflammation during atherogenesis is now a matter of intense investigation [1,2]. Basic science studies proved that elements belonging to both innate and adaptive immunity can be involved in the formation, progression and complication of atherosclerosis [2]. Plasma levels of circulating inflammatory molecules, such as C-reactive protein (CRP) and interleukin-6 (IL-6), have been shown to be predictive of future cardiovascular disease (CVD), and drugs which modify their levels can reduce the risk of myocardial infarction and stroke [3]. It has been known for years that hypertension represents an important risk factor for CVD and its treatment is mandatory to prevent future adverse events. To date, however, very little data are available concerning a potential link between inflammation and hypertension. Inflammation and hypertension may share some pathophysiological mechanisms, and this raises the question of whether the treatment of one of the two conditions could have some impact on the other.

1 October 2003 in Journal Of Hypertension
Verified
Journal Article
Closed access
MRMarcello Rattazzi
Marcello Rattazzi
MPMassimo Puato
Massimo Puato
EFElisabetta Faggin
Elisabetta Faggin
BBBarbara Bertipaglia
Barbara Bertipaglia
AZAlberto Zambon
Alberto Zambon
PPPaolo Pauletto
Paolo Pauletto
Recent advances in basic science have shown that atherosclerosis should be considered as a chronic inflammatory process, and that a pivotal role of inflammation is evident from initiation through progression and complication of atherosclerosis. In the past few years many studies have examined the potential for biochemical markers of inflammation to act as predictors of coronary heart disease (CHD) risk in a variety of clinical settings. Several large, prospective epidemiological studies have shown consistently that C-reactive protein (CRP) and interleukin-6 (IL-6) plasma levels are strong independent predictors of risk of future cardiovascular events, both in patients with a history of CHD and in apparently healthy subjects. These molecules could be useful to complement traditional risk factors, as well as to identify new categories of subjects prone to atherosclerosis development. An intriguing question is whether these inflammatory molecules simply represent sensitive markers of systemic inflammation or if they actively contribute to atherosclerotic lesion formation and instability. In this paper we will review the evidence concerning the cardiovascular prognostic value and the potential direct involvement of CRP and IL-6 in atherogenesis.

3 October 2013 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
MRMarcello Rattazzi
Marcello Rattazzi
EBE. Bertacco
E. Bertacco
AVA. Del Vecchio
A. Del Vecchio
MPM. Puato
M. Puato
EFE. Faggin
E. Faggin
PPP. Pauletto
P. Pauletto
Several clinical studies reported an increased prevalence and accelerated progression of aortic valve calcification among patients with end-stage renal disease when compared with subjects with normal kidney function. Recently, mechanisms of calcific valve degeneration have been further elucidated and many of the pathways involved could be amplified in patients with decreased renal function. In particular, calcium-phosphate balance, MGP metabolism, OPG/RANK/RANKL triad, fetuin-A mineral complexes and FGF-23/Klotho axis have been shown to be impaired among patients with advanced chronic kidney disease and could play a role during vascular/valve calcification. The scope of the present review is to summarize the clinical data and the pathophysiological mechanisms potentially involved in the link between renal function decline and the progression of aortic valve disease.

29 April 2011 in Circulation Research
Verified
Journal Article
Closed access
Gian Paolo FadiniGian Paolo Fadini
Gian Paolo Fadini
MAMattia Albiero
Mattia Albiero
LMLisa Menegazzo
Lisa Menegazzo
EBElisa Boscaro
Elisa Boscaro
SKSaula Vigili de Kreutzenberg
Saula Vigili de Kreutzenberg
AAAngelo Avogaro
Angelo Avogaro
Rationale:: Acquisition of a procalcific phenotype by resident or circulating cells is important for calcification of atherosclerotic plaques, which is common in diabetes. Objective:: We aim to identify and characterize circulating calcifying cells, and to delineate a pathophysiological role for these cells in type 2 diabetes. Methods and Results:: We demonstrate for the first time that a distinct subpopulation of circulating cells expressing osteocalcin and bone alkaline phosphatase (OC + BAP + ) has procalcific activity in vitro and in vivo. The study of naïve patients with chronic myeloid leukemia indicated that OC + BAP + cells have a myeloid origin. Myeloid calcifying OC + BAP + cells (MCCs) could be differentiated from peripheral blood mononuclear cells, and generation of MCCs was closely associated with expression of the osteogenic transcription factor Runx2. In gender-mismatched bone marrow–transplanted humans, circulating MCCs had a much longer half-life compared with OC − BAP − cells, suggesting they belong to a stable cell repertoire. The percentage of MCCs was higher in peripheral blood and bone marrow of type 2 diabetic patients compared with controls but was lowered toward normal levels by optimization of glycemic control. Furthermore, diabetic carotid endoarterectomy specimens showed higher degree of calcification and amounts of cells expressing OC and BAP in the α-smooth muscle actin–negative areas surrounding calcified nodules, where CD68 + macrophages colocalize. High glucose increased calcification by MCCs in vitro, and hypoxia may regulate MCC generation in vitro and in vivo. Conclusions:: These data identify a novel type of blood-derived procalcific cells potentially involved in atherosclerotic calcification of diabetic patients.